Personalis (NASDAQ:PSNL) Trading Down 4.1% - Here's Why

Key Points

• Personalis, Inc. shares dropped 4.1% on Friday, trading as low as $5.85, with a significant decline in trading volume of 90% from its average session.
• Several analysts have revised their ratings, with Wall Street Zen downgrading the stock from "hold" to "sell," while consensus estimates indicate a "Buy" rating and an average price target of $7.42.
• The company reported a quarterly earnings loss of ($0.23) per share, surpassing estimates but falling short on revenue, indicating a negative net margin of 113.70%.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) shares traded down 4.1% on Friday . The stock traded as low as $5.87 and last traded at $5.85. 104,175 shares were traded during mid-day trading, a decline of 90% from the average session volume of 1,045,348 shares. The stock had previously closed at $6.10.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Wall Street Zen cut shares of Personalis from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. BTIG Research set a $6.00 price objective on shares of Personalis in a research report on Wednesday, August 6th. HC Wainwright restated a "buy" rating and issued a $8.50 price objective on shares of Personalis in a research report on Monday. Finally, Guggenheim assumed coverage on shares of Personalis in a research report on Thursday, May 15th. They issued a "buy" rating and a $6.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Personalis has a consensus rating of "Buy" and an average target price of $7.42.

Personalis Trading Down 5.7%

The company has a market cap of $510.09 million, a P/E ratio of -4.51 and a beta of 1.76. The firm's 50 day moving average price is $5.53 and its 200-day moving average price is $4.85.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $17.20 million for the quarter, compared to analyst estimates of $20.12 million. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PSNL. Howland Capital Management LLC boosted its stake in Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company's stock worth $1,872,000 after acquiring an additional 2,500 shares during the last quarter. Man Group plc bought a new position in Personalis during the 2nd quarter worth approximately $324,000. BNP Paribas Financial Markets boosted its stake in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Bank of America Corp DE boosted its stake in Personalis by 10.5% during the 2nd quarter. Bank of America Corp DE now owns 222,011 shares of the company's stock worth $1,456,000 after acquiring an additional 21,009 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in Personalis by 1,172.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 329,865 shares of the company's stock worth $2,164,000 after acquiring an additional 303,933 shares during the last quarter. Institutional investors own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.